<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752842</url>
  </required_header>
  <id_info>
    <org_study_id>201112122</org_study_id>
    <secondary_id>P20HL113444-01</secondary_id>
    <nct_id>NCT01752842</nct_id>
  </id_info>
  <brief_title>Lipid Biomarkers for Diabetic Heart Disease</brief_title>
  <official_title>Lipid Biomarkers for Diabetic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leducq Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether lowering the delivery of excess fats to the heart in persons
      with type-2 diabetes mellitus improves heart muscle function. The investigators will also
      test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic
      heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening procedures include 12-hour fasting blood draw, urine pregnancy testing for females,
      completion of medical history questionnaire, and stress echocardiography to rule out coronary
      artery disease or cardiomyopathy.

      Subjects who meet screening criteria will return for visit 2, which consists of a urine
      collection, 12-hour fasting blood draw, dual-energy X-ray absorptiometry (DXA) for body
      composition, magnetic resonance spectroscopy analysis of the liver, and resting
      echocardiogram for analysis of heart structure and function. Subjects will then be randomized
      to treatment with fenofibrate (160 mg/d) or an identical-appearing placebo for 12 weeks. They
      will be asked to continue their usual medications, diet and physical activity. Subjects will
      receive a pedometer to wear daily to track their physical activity. Subjects will meet with
      dietitians from the Lifestyle Intervention Core to complete a 24-hour dietary recall. They
      will be instructed to record their daily blood glucose concentrations, distance walked and
      any side effects, illnesses or stresses in a study-supplied log. Subjects will be instructed
      to either email or fax the log to the study coordinator each week (or discuss by phone).

      Subjects will return 6 weeks after starting intervention for visit 3 to ensure their medical
      safety. Procedures at this visit include an interim medical history, urine pregnancy test for
      females, blood draw to rule out untoward effects of the study drug on liver or kidney
      function, pill count to assess compliance, review of logs of blood glucose, distance walked,
      and side effects, illnesses or stresses, and meeting with a dietitian for a 24-hour dietary
      recall.

      Subjects will continue to take their study medication/placebo and keep logs of blood glucose
      levels, distance walked, and side effects, illnesses and stresses for another 6 weeks. They
      will return for visit 4 after 12 total weeks of intervention. Visit 4 involves a urine
      collection, 12-hour fasting blood draw, review of subject logs, pill count, and 24-hour
      dietary recall. In addition, magnetic resonance spectroscopy analysis of the liver and
      resting echocardiogram analysis of the heart will be performed to determine if there have
      been any changes in liver fat or heart function during the 12-week intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cardiac Diastolic Function as Measured by E' (cm/s)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C24:0/C16:0 Ceramide Ratio</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Mass spectrometry-based quantification of the ratio of C24:0 ceramide to C16:0 ceramide in plasma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One fenofibrate 160 mg capsule per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for fenofibrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One inert sugar pill per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Tricor</other_name>
    <other_name>Triglide</other_name>
    <other_name>Antara</other_name>
    <other_name>Lipofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for fenofibrate</intervention_name>
    <arm_group_label>Placebo for fenofibrate</arm_group_label>
    <other_name>Sugar pill manufactured to mimic Fenofibrate 160 mg capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

        Exclusion Criteria:

          -  body weight &gt; 300 lb.

          -  HIV

          -  hypothyroid

          -  steroid medication, fenofibrate

          -  smoking

          -  BP &gt; 140/90

          -  heart disease

          -  pregnant or lactating

          -  consumption of &gt; 5 alcoholic drinks/wk

          -  creatinine &gt; 1.5 mg/dL

          -  hematocrit &lt; 28
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean E Schaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 Jul;34(1):29-34.</citation>
    <PMID>4835750</PMID>
  </reference>
  <reference>
    <citation>Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA. 1974 Sep 23;229(13):1749-54.</citation>
    <PMID>4278055</PMID>
  </reference>
  <reference>
    <citation>Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004 May 11;109(18):2191-6. Epub 2004 May 3.</citation>
    <PMID>15123530</PMID>
  </reference>
  <reference>
    <citation>Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006 Feb 7;47(3):598-604. Epub 2006 Jan 18.</citation>
    <PMID>16458143</PMID>
  </reference>
  <reference>
    <citation>Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003 Mar;49(3):417-23.</citation>
    <PMID>12594743</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004 Nov;18(14):1692-700.</citation>
    <PMID>15522914</PMID>
  </reference>
  <reference>
    <citation>Griffin JA, Osborn BW, Smithline HA. The impact of diabetes on hospital admissions, length of stay and mortality in emergency department patients with acute decompensated heart failure without ischemia. Acad Emerg Med. 2005;12:s97</citation>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <results_first_submitted>February 7, 2019</results_first_submitted>
  <results_first_submitted_qc>February 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic Cardiomyopathy</keyword>
  <keyword>Triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from clinics, practices and laboratories within the Barnes-Jewish Hospital consortium, Volunteer for Health and Diabetes Research Connections recruitment programs at Washington University School of Medicine, and through local advertisements, posters, emails and flyers. Dates of recruitment were from May 2013 to October 2017.</recruitment_details>
      <pre_assignment_details>Potential subjects were given the approved consent form to consider. If interested, they were scheduled for a screening visit in the Center for Applied Research Sciences. The consent form was signed before any testing took place. Blood and urine were collected and a cardiac stress test was performed to evaluate the subject for eligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fenofibrate</title>
          <description>Participants were instructed to take one fenofibrate 160 mg capsule every day for 12 weeks
Fenofibrate</description>
        </group>
        <group group_id="P2">
          <title>Placebo for Fenofibrate</title>
          <description>Participants were instructed to take one inert sugar pill every day for 12 weeks
Placebo for fenofibrate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fenofibrate</title>
          <description>One fenofibrate 160 mg capsule per day for 12 weeks
Fenofibrate</description>
        </group>
        <group group_id="B2">
          <title>Placebo for Fenofibrate</title>
          <description>One inert sugar pill per day for 12 weeks
Placebo for fenofibrate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="8.2"/>
                    <measurement group_id="B2" value="54.6" spread="8.3"/>
                    <measurement group_id="B3" value="54.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Diastolic Function (E')</title>
          <population>Study-specific baseline characteristics were determined for subjects who completed the 12-week intervention only.</population>
          <units>cm/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.30" spread="1.70"/>
                    <measurement group_id="B2" value="7.99" spread="1.78"/>
                    <measurement group_id="B3" value="8.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Systolic Function (Fractional Shortening)</title>
          <population>Study-specific baseline characteristics were determined for subjects who completed the 12-week intervention only.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="7"/>
                    <measurement group_id="B2" value="38" spread="6"/>
                    <measurement group_id="B3" value="38.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C24:0/C16:0 ceramides</title>
          <population>Study-specific baseline characteristics were determined for subjects who completed the 12-week intervention only.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="2.4"/>
                    <measurement group_id="B2" value="12.4" spread="3"/>
                    <measurement group_id="B3" value="11.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiac Diastolic Function as Measured by E' (cm/s)</title>
        <description>Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All participants for whom E' (diastolic function) was measured at baseline and 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>Participants were instructed to take one fenofibrate 160 mg capsule every day for 12 weeks
Fenofibrate</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Fenofibrate</title>
            <description>Participants were instructed to take one inert sugar pill every day for 12 weeks
Placebo for fenofibrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Diastolic Function as Measured by E' (cm/s)</title>
          <description>Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline.</description>
          <population>All participants for whom E' (diastolic function) was measured at baseline and 12 weeks.</population>
          <units>cm/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="1.35"/>
                    <measurement group_id="O2" value="0.55" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference of mean change of cardiac diastolic function as measured by E' (cm/s) between placebo and Fenofibrate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Power calculation is based on assumption that treatment with Fenofibrate will lead to 11% decrease in plasma TG and ceramide biomarkers. We also assume that there will be no significant change in ceramides without intervention. Based on these assumptions, 86 subjects are required to have 90% chance of detecting a decrease in the primary outcome measure from 1.29 in the placebo group to 1.15 in the Fenofibrate group.</non_inferiority_desc>
            <p_value>0.07</p_value>
            <p_value_desc>This P-value is based on ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>ANCOVA was used to compare mean change of cardiac diastolic function adjusting for body fat percent, baseline values of BMI, diastolic/systolic blood pressure, HbA1c, fasting glucose, triglycerides, ethnicity, gender and race.</estimate_desc>
            <other_analysis_desc>Two-sample t-test was used to compare baseline mean values of biomarkers. All statistical tests are two-sided at significance level 0.05.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent</title>
        <description>Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All participants for whom fractional shortening was measured at baseline and 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>Participants were instructed to take one fenofibrate 160 mg capsule every day for 12 weeks
Fenofibrate</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Fenofibrate</title>
            <description>Participants were instructed to take one inert sugar pill every day for 12 weeks
Placebo for fenofibrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent</title>
          <description>Change was measured by echocardiography and was calculated as the value at 12 weeks minus the value at baseline.</description>
          <population>All participants for whom fractional shortening was measured at baseline and 12 weeks.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.090"/>
                    <measurement group_id="O2" value="0.030" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference of mean change of fractional shortening percent between placebo and Fenofibrate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Power calculation is based on assumption that treatment with Fenofibrate will lead to 11% decrease in plasma TG and ceramide biomarkers. We also assume that there will be no significant change in ceramides without intervention. Based on these assumptions, 86 subjects are required to have 90% chance of detecting a decrease in the primary outcome measure from 1.29 in the placebo group to 1.15 in the Fenofibrate group.</non_inferiority_desc>
            <p_value>0.8128</p_value>
            <p_value_desc>This P-value is based on ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0058</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0418</ci_lower_limit>
            <ci_upper_limit>0.0543</ci_upper_limit>
            <estimate_desc>ANCOVA was used to compare mean change of outcome adjusting for body fat percent, demographic variables and baseline biomarkers.</estimate_desc>
            <other_analysis_desc>Two-sample t-test was used to compare baseline mean values of biomarkers. All statistical tests are two-sided at significance level 0.05.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C24:0/C16:0 Ceramide Ratio</title>
        <description>Mass spectrometry-based quantification of the ratio of C24:0 ceramide to C16:0 ceramide in plasma.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>All participants for whom C24:0 and C16:0 ceramides were measured at baseline and 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>Participants were instructed to take one fenofibrate 160 mg capsule every day for 12 weeks
Fenofibrate</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Fenofibrate</title>
            <description>Participants were instructed to take one inert sugar pill every day for 12 weeks
Placebo for fenofibrate</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C24:0/C16:0 Ceramide Ratio</title>
          <description>Mass spectrometry-based quantification of the ratio of C24:0 ceramide to C16:0 ceramide in plasma.</description>
          <population>All participants for whom C24:0 and C16:0 ceramides were measured at baseline and 12 weeks.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.66"/>
                    <measurement group_id="O2" value="-0.03" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference of mean change of C24:0/C16:0 ceramide ratio between placebo and Fenofibrate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Power calculation is based on assumption that treatment with Fenofibrate will lead to 11% decrease in plasma TG and ceramide biomarkers. We also assume that there will be no significant change in ceramides without intervention. Based on these assumptions, 86 subjects are required to have 90% chance of detecting a decrease in the primary outcome measure from 1.29 in the placebo group to 1.15 in the Fenofibrate group.</non_inferiority_desc>
            <p_value>0.0034</p_value>
            <p_value_desc>This P-value is based on ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA was used to compare mean change of outcome adjusting for body fat percent, demographic variables and baseline biomarkers.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.93</ci_lower_limit>
            <ci_upper_limit>-0.65</ci_upper_limit>
            <other_analysis_desc>Two-sample t-test was used to compare baseline mean values of biomarkers. All statistical tests are two-sided at significance level 0.05.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the 12 weeks of intervention.</time_frame>
      <desc>Participants self-reported side-effects weekly during intervention, and an interim study visit took place half-way through the 12 weeks so safety labs could be obtained.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fenofibrate</title>
          <description>Participants were instructed to take one fenofibrate 160 mg capsule every day for 12 weeks
Fenofibrate</description>
        </group>
        <group group_id="E2">
          <title>Placebo for Fenofibrate</title>
          <description>Participants were instructed to take one inert sugar pill every day for 12 weeks
Placebo for fenofibrate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash/itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Findings of this study cannot be extended to those who do not fit the entry criteria. Also, since this was a targeted lipidomics study, there may be changes in other lipid species after treatment with fenofibrate that were not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jean E. Schaffer, MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-8717</phone>
      <email>jschaff@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

